MIRA Pharmaceuticals Achieves 100% Reversal Of Neuropathic Pain With Oral Ketamir-2 In A Rat Study, Outperforming Oral Ketamine And Showcasing Its Potential As A Significant Treatment For Neuropathic Pain, Setting The Stage For Further Clinical Trials.
MIRA Pharmaceuticals Achieves 100% Reversal Of Neuropathic Pain With Oral Ketamir-2 In A Rat Study, Outperforming Oral Ketamine And Showcasing Its Potential As A Significant Treatment For Neuropathic Pain, Setting The Stage For Further Clinical Trials.
米拉制药在大鼠研究中使用口服Ketamir-2成功实现了100%的神经病理性疼痛逆转，胜过了口服氯胺酮，并展示了其作为神经病理性疼痛重要治疗的潜力，为进一步的临床试验铺平了道路。
MIRA Pharmaceuticals Achieves 100% Reversal Of Neuropathic Pain With Oral Ketamir-2 In A Rat Study, Outperforming Oral Ketamine And Showcasing Its Potential As A Significant Treatment For Neuropathic Pain, Setting The Stage For Further Clinical Trials.
米拉制药在大鼠研究中使用口服Ketamir-2成功实现了100%的神经病理性疼痛逆转，胜过了口服氯胺酮，并展示了其作为神经病理性疼痛重要治疗的潜力，为进一步的临床试验铺平了道路。